Operator of a bio-pharmaceutical contract development and manufacturing organization (CDMO).
Operator of a bio-pharmaceutical contract development and manufacturing organization (CDMO).
Drug Discovery📍 Nanjing, ChinaFounded 2009
Current Valuation
$880M
as of 2021-Q2
PRIVATE
QL Price
$880M
0% vs last round
QuantLogix's current estimate for GenScript ProBio, published 2026-11-12 — in line with the last disclosed round of $880M (2021-Q2).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round
$880M
2021-Q2
weight 0.02
How this price has held up
No round has priced for GenScript ProBio since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-11-12 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, GenScript ProBio, 2026-11-12 (76d54710489d5025).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is GenScript ProBio going public?
No. GenScript ProBio is private and has not filed to go public. There is no S-1 on file.
What is GenScript ProBio's valuation in 2026?
GenScript ProBio is valued at $880M as of 2021-Q2, set by its Series A ($150M, May 2021). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has GenScript ProBio filed an S-1?
No public S-1 is on file for GenScript ProBio.
How much has GenScript ProBio raised?
GenScript ProBio has raised $150M in total, most recently a Series A of $150M in May 2021.
Is GenScript ProBio publicly traded — can you buy GenScript ProBio stock?
No. GenScript ProBio is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for GenScript ProBio on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2009
HQ
Nanjing, China
Employees
2,038
Total Raised
$150M
Last Round
Series A — $150M (May 2021)
IPO Status
private
Fundraising Status
Series A · $150M · 5y 6mo ago
privateTotal raised $150M
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series A
$150M
May 2021
—
$880M
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for GenScript ProBio — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-11-12. Re-checked weekly.
Talent Signal
Hiring trend
▼ Hiring downtrend
-12% vs 2026-09
Open roles
72
via greenhouse
Product-build share
28%
engineering, research, product, design
Trajectory
tightening
balanced build + GTM — 28% builders vs 72% go-to-market/G&A — scaling both sides.
Open roles trending down; no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Associate Principal / Principal Scientist (Protein Science)Automation EngineerAutomation Service EngineerEnterprise AI Agent Development EngineerFormulation ScientistGlobal Product Manager, Emerging Applications
Counted from GenScript ProBio's live job board as of 2026-10-16; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
BiotechnologyGeneticsManufacturing
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2021-Q2. Refreshed quarterly.